06185 康希诺生物
按盘价 
18.820 +0.460 (+2.505%) | 2023/12 - 末期 人民币() | 2022/12 人民币() | 2021/12 人民币() | 2020/12 人民币() | 2019/12 人民币() | |
| 经营活动之现金流量 | (916,252,000) | (1,887,599,000) | 2,014,557,000 | (469,389,000) | (170,189,000) |
| 投资活动之现金流量 | (441,622,000) | (1,191,955,000) | (2,531,270,000) | (182,713,000) | (797,770,000) |
| 融资活动之现金流量 | (7,582,000) | 854,602,000 | 1,559,922,000 | 4,923,518,000 | 1,090,826,000 |
| 现金及等同现金之增加/(减少) | (1,365,456,000) | (2,224,952,000) | 1,043,209,000 | 4,271,416,000 | 122,867,000 |
| 期初之现金及现金等价物 | 3,391,268,000 | 5,455,456,000 | 4,446,029,000 | 201,973,000 | 57,381,000 |
| 汇率变动之影响 | 20,287,000 | 160,764,000 | (33,782,000) | (27,360,000) | 21,725,000 |
| 其他 | 0 | 0 | 0 | 0 | 0 |
| 期末之现金及现金等价物 | 2,046,099,000 | 3,391,268,000 | 5,455,456,000 | 4,446,029,000 | 201,973,000 |
| 备注： | 实时报价更新时间为26/04/2024 18:00 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -1,482,732,000 |
| 增长率 | 63.040% |
| 每股盈利/(亏损) | RMB -6.010 |
| 每股账面资产净值 (¥) | RMB 21.316 |